Background: Since December 2019, COVID-19 has widely spread throughout the world, causing thousands of deaths. Clinical characteristics of COVID-19 patie
Reviewers: Yoh Takuwa (Kanazawa University) | 📒📒📒◻️◻️ • Hideru Obinata (Gunma University) | 📒📒📒◻️◻️ • Markus Gräler (Jena University Hospital) | 📙📙◻️◻️◻️ • Georgios Grammatikos (Goethe University Frankfurt) | 📒📒📒◻️◻️
To read the original manuscript, click the link above.
Summary of Reviews: This potentially informative article with some methodological flaws suggests that serum Sphingosine-1-Phosphate (S1P) is associated with COVID-19 severity. Further research is needed to understand if serum S1P could be provided therapeutically to reduce COVID-19 severity.
Reviewer 1 (Yoh Takuwa) | 📒📒📒◻️◻️
Reviewer 2 (Hideru Obinata) | 📒📒📒 ◻️◻️
Reviewer 3 (Markus Gräler) | 📙📙 ◻️◻️◻️
Reviewer 4 (Georgios Grammatikos) | 📒📒📒 ◻️◻️
RR:C19 Strength of Evidence Scale Key
📕 ◻️◻️◻️◻️ = Misleading
📙📙 ◻️◻️◻️ = Not Informative
📒📒📒 ◻️◻️ = Potentially Informative
📗📗📗📗◻️ = Reliable
📘📘📘📘📘 = Strong
To read the reviews, click the links below.